Description: CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Home Page: www.calcimedica.com
505 Coast Boulevard South
La Jolla,
CA
92037
United States
Phone:
858-952-5500
Officers
| Name | Title |
|---|---|
| Dr. A. Rachel Leheny Ph.D. | CEO & Director |
| Mr. Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board |
| Dr. Kenneth A. Stauderman Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Michael J. Dunn M.B.A., MBA | President & COO |
| Dr. Anjana Rao Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Patrick Hogan Ph.D. | Co-Founder and Scientific Advisor |
| Dr. Stefan Feske M.D. | Co-Founder and Scientific Advisor |
| Mr. John M. Dunn J.D. | General Counsel |
| Dr. Sudarshan Hebbar M.D. | Chief Medical Officer |
| Ms. Raven D. Jaeger M.S. | Chief Regulatory Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.1655 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-09-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |